Get Premium to unlock powerful stock data

Birchview Capital, LP Buys ContraFect Corp, Soleno Therapeutics Inc, Prothena Corp PLC, Sells Acceleron Pharma Inc, , Dicerna Pharmaceuticals Inc

Author's Avatar
insider
Nov 12, 2021
Article's Main Image
Burlington, VT, based Investment company Birchview Capital, LP (Current Portfolio) buys ContraFect Corp, Soleno Therapeutics Inc, Prothena Corp PLC, Cytokinetics Inc, Gossamer Bio Inc, sells Acceleron Pharma Inc, , Dicerna Pharmaceuticals Inc, HOOKIPA Pharma Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Birchview Capital, LP. As of 2021Q3, Birchview Capital, LP owns 65 stocks with a total value of $147 million. These are the details of the buys and sells.

For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolio

These are the top 5 holdings of Birchview Capital, LP
  1. Bristol-Myers Squibb Co (BMY) - 796,106 shares, 32.05% of the total portfolio.
  2. Accelerate Diagnostics Inc (AXDX) - 2,252,388 shares, 8.91% of the total portfolio. Shares added by 0.87%
  3. Biodesix Inc (BDSX) - 1,104,953 shares, 6.18% of the total portfolio.
  4. Quidel Corp (QDEL) - 59,684 shares, 5.73% of the total portfolio.
  5. Neurocrine Biosciences Inc (NBIX) - 80,200 shares, 5.23% of the total portfolio.
New Purchase: ContraFect Corp (CFRX)

Birchview Capital, LP initiated holding in ContraFect Corp. The purchase prices were between $3.19 and $4.43, with an estimated average price of $3.89. The stock is now traded at around $4.010000. The impact to a portfolio due to this purchase was 0.55%. The holding were 200,000 shares as of 2021-09-30.

New Purchase: Soleno Therapeutics Inc (SLNO)

Birchview Capital, LP initiated holding in Soleno Therapeutics Inc. The purchase prices were between $0.8 and $1.12, with an estimated average price of $0.93. The stock is now traded at around $0.770100. The impact to a portfolio due to this purchase was 0.55%. The holding were 876,899 shares as of 2021-09-30.

New Purchase: Gossamer Bio Inc (GOSS)

Birchview Capital, LP initiated holding in Gossamer Bio Inc. The purchase prices were between $7.25 and $13.23, with an estimated average price of $9.2. The stock is now traded at around $11.950000. The impact to a portfolio due to this purchase was 0.34%. The holding were 40,000 shares as of 2021-09-30.

New Purchase: AVEO Pharmaceuticals Inc (AVEO)

Birchview Capital, LP initiated holding in AVEO Pharmaceuticals Inc. The purchase prices were between $5.12 and $6.89, with an estimated average price of $5.99. The stock is now traded at around $7.390000. The impact to a portfolio due to this purchase was 0.17%. The holding were 40,000 shares as of 2021-09-30.

New Purchase: IVERIC bio Inc (ISEE)

Birchview Capital, LP initiated holding in IVERIC bio Inc. The purchase prices were between $7.07 and $17.5, with an estimated average price of $10.82. The stock is now traded at around $16.890000. The impact to a portfolio due to this purchase was 0.17%. The holding were 15,000 shares as of 2021-09-30.

New Purchase: iRhythm Technologies Inc (IRTC)

Birchview Capital, LP initiated holding in iRhythm Technologies Inc. The purchase prices were between $41.91 and $65.79, with an estimated average price of $53.06. The stock is now traded at around $105.980000. The impact to a portfolio due to this purchase was 0.16%. The holding were 4,000 shares as of 2021-09-30.

Added: Prothena Corp PLC (PRTA)

Birchview Capital, LP added to a holding in Prothena Corp PLC by 33.06%. The purchase prices were between $48.2 and $78.89, with an estimated average price of $62.15. The stock is now traded at around $56.920000. The impact to a portfolio due to this purchase was 0.48%. The holding were 40,247 shares as of 2021-09-30.

Added: Cytokinetics Inc (CYTK)

Birchview Capital, LP added to a holding in Cytokinetics Inc by 150.00%. The purchase prices were between $18.54 and $35.74, with an estimated average price of $29.35. The stock is now traded at around $39.560000. The impact to a portfolio due to this purchase was 0.37%. The holding were 25,000 shares as of 2021-09-30.

Added: Protagonist Therapeutics Inc (PTGX)

Birchview Capital, LP added to a holding in Protagonist Therapeutics Inc by 280.00%. The purchase prices were between $12.95 and $49.69, with an estimated average price of $42.78. The stock is now traded at around $36.710000. The impact to a portfolio due to this purchase was 0.34%. The holding were 38,000 shares as of 2021-09-30.

Added: Aziyo Biologics Inc (AZYO)

Birchview Capital, LP added to a holding in Aziyo Biologics Inc by 66.67%. The purchase prices were between $6.75 and $9.52, with an estimated average price of $8.18. The stock is now traded at around $6.000000. The impact to a portfolio due to this purchase was 0.1%. The holding were 50,000 shares as of 2021-09-30.

Added: Apellis Pharmaceuticals Inc (APLS)

Birchview Capital, LP added to a holding in Apellis Pharmaceuticals Inc by 50.00%. The purchase prices were between $31.4 and $69.84, with an estimated average price of $56.51. The stock is now traded at around $41.710000. The impact to a portfolio due to this purchase was 0.09%. The holding were 12,000 shares as of 2021-09-30.

Added: Kiniksa Pharmaceuticals Ltd (KNSA)

Birchview Capital, LP added to a holding in Kiniksa Pharmaceuticals Ltd by 50.00%. The purchase prices were between $11.39 and $16.23, with an estimated average price of $13.03. The stock is now traded at around $13.092000. The impact to a portfolio due to this purchase was 0.08%. The holding were 30,000 shares as of 2021-09-30.

Sold Out: (TBIO)

Birchview Capital, LP sold out a holding in . The sale prices were between $27.64 and $37.85, with an estimated average price of $34.42.

Sold Out: Dicerna Pharmaceuticals Inc (DRNA)

Birchview Capital, LP sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $19.68 and $39.99, with an estimated average price of $27.67.

Sold Out: HOOKIPA Pharma Inc (HOOK)

Birchview Capital, LP sold out a holding in HOOKIPA Pharma Inc. The sale prices were between $5.89 and $9.35, with an estimated average price of $7.28.

Reduced: Acceleron Pharma Inc (XLRN)

Birchview Capital, LP reduced to a holding in Acceleron Pharma Inc by 42.84%. The sale prices were between $115.25 and $182.78, with an estimated average price of $130.74. The stock is now traded at around $173.740000. The impact to a portfolio due to this sale was -0.61%. Birchview Capital, LP still held 10,672 shares as of 2021-09-30.



Here is the complete portfolio of Birchview Capital, LP. Also check out:

1. Birchview Capital, LP's Undervalued Stocks
2. Birchview Capital, LP's Top Growth Companies, and
3. Birchview Capital, LP's High Yield stocks
4. Stocks that Birchview Capital, LP keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus